Background: Breast cancer is one of the most common malignancies found among women in India. Haematological parameters have been shown to predict severity, mortality and treatment follow-up in breast cancer patients. The aim of the study was to compare haematological parameters along with effect of chemotherapy and radiotherapy in different stages of breast cancer patients.Methods: Total 235 human subjects were taken in the study. Out of which 100 normal ages matched healthy subjects were considered as controls and 135 breast cancer patients subjects as cases which were further divided into their respective stages according to TNM classification.Results: Estimation of haematological parameters was done by Sysmex Automated Hematology Analyzer Kx-21. The statistical differences between cases and control were determined by using student independent sample t-test.Conclusions: We found hemoglobin level, polymorphs, lymphocytes, monocytes and RBC count were statistically reduce (p<0.05) while other parameters were non-significant as compared to control healthy subjects. We also found deranged haematological parameters in all four stages of breast cancer. The data also indicated that patients which were on combined therapies i.e. radio and chemo have more deranged and decreased levels of haematological parameters as compared to individual therapies.
Introduction:The potential risk of prolongation of treatment time in cervical cancer has been reported for many low-
Conclusion:The results of this study suggest that to achieve better treatment outcome, avoid treatment prolongation and overall treatment time should be less than 50 days.
Background: Carcinoma of uterine cervix is the commonest cancer affecting females in developing countries. Concurrent chemoradiation has remained the sole definitive treatment available in the advanced stages. The study was planned to take the advantage of radiosensitisation accruing due to chemotherapy at the time of brachytherapy, when approximately 40% of total tumor dose is applied. Subjects and Methods: Sixty-four patients were enrolled who had locally advanced uterine cervix carcinoma (Federation of Gynecology and Obstetrics Stage IIB-IVA) from July 2011 to May 2013 for concurrent chemotherapy and intracavitory brachytherapy after completion of concurrent chemotherapy and external beam radiotherapy followed by three insertion of brachytherapy separated by a week by flexitron brachytherapy unit to Point A, for each application was 6 Gy by high dose rate. Cisplatin was given (35 mg/m 2 ) 1 day before brachytherapy in each application. Results: At medium follow-up of 19 months (range 8-30 months) clinical complete response rate was found to be 89% at 3 months of follow-up. Acute side effect as nausea and vomiting Grades I and II were recorded as 55% and 28% respectively, no renal dysfunction and no thrombocytopenia were encountered. No patients had Grade IV or life threatening toxicity. Overall survival and disease free survival after 30 months of follow-up is 88% and 75% respectively. Conclusion: Use of concurrent chemotherapy with brachytherapy is effective and feasible with acceptable toxicity for locally advanced carcinoma of the uterine cervix.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.